In February 2026, Robert F. Kennedy Jr. discussed upcoming peptide regulation changes during an appearance on the The Joe Rogan Experience. During the conversation on February 27, 2026, he explained that the U.S. Food and Drug Administration may remove around 14 peptides from the restrictive Category 2 list.
If the change moves forward, licensed compounding pharmacies could legally prepare these peptides under federal guidelines.
For laboratories and scientific researchers working with peptides, this potential shift could significantly improve access to regulated materials. Below is a breakdown of what the announcement means and how it may affect research moving forward.
Table of Contents
RFK Jr.’s View on Current FDA Restrictions
Before becoming head of the United States Department of Health and Human Services, RFK Jr. frequently criticized the FDA’s approach to regulating emerging therapies.
In October 2024, he posted on X (formerly Twitter) claiming the agency had been overly aggressive toward several health-related treatments and technologies, including peptides, stem cells, and certain nutritional therapies.
After taking office in early 2025, he continued advocating for regulatory reforms. His policy approach focused on three main goals:
- Expanding safe treatment options for patients
- Reducing reliance on unregulated international suppliers
- Directing oversight toward proven safety risks rather than theoretical concerns
These views have shaped the ongoing discussion around peptide regulations.
How the FDA Classifies Peptides for Compounding
Peptides used in pharmacy compounding are regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA groups these substances into three categories based on available safety data.
Category 1 – Eligible for Compounding
Peptides placed in this group have sufficient safety information available. Pharmacies may compound them with a valid prescription from a licensed medical provider.
Category 2 – Restricted Substances
Compounds in this category are considered to have potential safety issues, such as immune reactions or contamination concerns. Because of these risks, pharmacies are not allowed to compound them legally.
Category 3 – Insufficient Data
This category includes substances that lack enough evidence for the FDA to determine whether compounding is appropriate. Additional studies are required before they can be reconsidered.
Between late 2023 and December 2024, the FDA moved 19 peptides from Category 1 into Category 2, effectively blocking pharmacies from preparing them. As a result, many researchers began sourcing peptides from international or research-only vendors.
Why the FDA Restricted These Peptides
The FDA cited several reasons for tightening the regulations:
- Limited human clinical data
- Manufacturing and quality concerns
- Theoretical safety risks
However, critics—including RFK Jr.—argued that the decision was largely precautionary rather than evidence-based. They claimed the restrictions unintentionally pushed researchers toward unregulated suppliers, which could create greater safety issues.
Key Highlights From the February 2026 Announcement
During the podcast discussion, RFK Jr. suggested that the FDA may reconsider many of the earlier restrictions.
According to his comments:
- Roughly 14 of the 19 peptides could be moved out of Category 2
- Compounding pharmacies might once again prepare them legally
- Restricting compounding created demand in unregulated markets
- Restoring controlled pharmacy access may improve safety
He emphasized that the previous restrictions were not necessarily tied to documented harm, but rather precautionary concerns.
Important clarification:
Even if the change happens, these peptides would not be FDA-approved medications. They could only be compounded with a prescription and would still be considered experimental therapies.
Possible Timeline for the Policy Update
If the regulatory review proceeds as expected, the process may follow this schedule:
March–April 2026
Public comment period lasting about 30 days
May–June 2026
The FDA reviews feedback and releases final guidance
July 2026 and beyond
State regulators begin implementing the updated rules
In most cases, peptide prescriptions will likely remain self-pay treatments, since insurance providers rarely cover experimental compounds.
Peptides That Were Originally Moved to Category 2
The FDA previously restricted the following 19 peptides:
- BPC-157
- Cathelicidin LL-37
- DSIP (Emideltide)
- Epitalon
- GHK-Cu
- GHRP-2
- GHRP-6
- Ipamorelin
- Kisspeptin-10
- KPV
- Melanotan II
- PEG-MGF
- MOTS-C
- Semax
- Thymosin beta-4 fragment
- AOD-9604
- CJC-1295
- Selank
- Thymosin Alpha-1
These compounds are primarily investigated in laboratory and animal research related to tissue regeneration, immune signaling, metabolism, and hormone pathways.
Peptides Expected to Return to Compounding
Industry observers believe around 14 peptides could be reconsidered for pharmacy compounding, including:
- BPC-157
- Thymosin Alpha-1
- Thymosin Beta-4 (TB-500)
- PT-141 (Bremelanotide)
- Ipamorelin
- GHRP-2
- GHRP-6
- CJC-1295
- Selank
- Semax
- Hexarelin
- DSIP
- Epitalon
- Pinealon
However, some substances are expected to remain restricted, such as:
- Melanotan II
- Cathelicidin LL-37
Other peptides—including PEG-MGF and Kisspeptin-10—may still be under review.
As of September 2024, five peptides had already been undergoing regulatory evaluation: CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank.
What This Means for Scientific Research
Better Access to Regulated Materials
Category 2 restrictions previously limited legal access to many peptides. Researchers often relied on international suppliers with inconsistent quality standards.
Allowing pharmacy compounding could provide:
- Higher purity materials
- Better quality control
- Traceable manufacturing processes
- Reduced contamination risks
This is particularly valuable for laboratory studies and preclinical experiments.
Potential Growth in Clinical Studies
Improved access could encourage more human clinical trials investigating peptides such as:
- BPC-157 for inflammation and healing
- Thymosin Alpha-1 for immune regulation
- TB-500 for tissue recovery
Over the next several years, this could lead to additional publications, funding opportunities, and formal clinical guidelines.
However, research involving humans still requires:
- Institutional Review Board (IRB) approval
- Investigational New Drug (IND) authorization when applicable
Researchers Must Still Follow Regulations
Even with reclassification, peptides would not automatically become approved medications.
Researchers must continue to comply with regulatory standards, including:
- Proper labeling for laboratory research use
- Avoiding claims related to unapproved medical treatments
- Following federal and state laws governing experimental compounds
Ongoing Safety Considerations
The FDA’s earlier concerns about peptide safety remain relevant.
Potential risks include:
- Immune responses
- Product contamination
- Variability in manufacturing quality
Because of this, researchers should maintain strict monitoring protocols and stay updated on regulatory developments.
It is also important to note that personal use without a prescription remains illegal.
Possible Effects on the Peptide Industry
If these policy adjustments move forward, several industry trends may follow:
- Increased investment in peptide drug development
- More patents for peptide-based treatments
- Expansion of telemedicine prescribing services
- Greater involvement from pharmaceutical companies
If a peptide eventually receives full FDA drug approval, suppliers selling research-only versions may face new restrictions.
For that reason, laboratories and vendors should regularly monitor updates from:
- The U.S. Food and Drug Administration
- The United States Department of Health and Human Services
- Official federal guidance documents
Final Thoughts
The discussion in February 2026 signals a potential shift in how peptide compounds are regulated in the United States. RFK Jr.’s position aims to strike a balance between scientific progress and patient safety.
For researchers, the proposed changes could mean better access to regulated materials and expanded opportunities for scientific study.
However, compliance, transparency, and responsible research practices will remain essential as the regulatory landscape continues to evolve.
Disclaimer:
The information presented in this article is based on publicly available sources. Readers should confirm details through official announcements and regulatory guidance.